Microsoft Word - March[removed]PT Decisions - Insulin aspart - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2014-07-29 11:11:27 Endocrine system Peptide hormones Recombinant proteins Diabetes Anti-diabetic drugs Humulin Insulin pen Exenatide Insulin aspart Eli Lilly and Company Chemistry Biology		Microsoft Word - March[removed]PT Decisions Add to Reading List Source URL: chpw.org Download Document from Source Website File Size: 55,77 KB Share Document on Facebook

	Strensiq, INN-asfotase alfa DocID: 1rcrc - View Document
	This material is intended for Canadian media only. Faster-acting insulin aspart showed a statistically significant reduction in HbA1c in type 1 diabetes and a comparable HbA1c reduction in type 2 diabetes versus NovoRap DocID: 1oyf7 - View Document
	■ Medical Safety Information Pharmaceuticals and Medical Devices Agency http://www.pmda.go.jp/english/service/medical_info.html No. 37 April, 2013 DocID: 18MwM - View Document
	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NovoLog® Mixsafely and effectively. See full prescribing information for NovoLog® Mix 70/30. ——— ADV DocID: 17Bn5 - View Document
	PDF Document DocID: 17c0f - View Document